TGT Stock Study (2-12-23)
Posted by Mark on December 8, 2022 at 06:43 | Last modified: March 8, 2023 10:36I recently* did a stock study on Target Corp. (TGT) with a closing price of $170.02.
Value Line writes:
> Target Corp.’s operations consisted of 1,926 discount stores,
> of which 1,528 were owned, in the U.S., mostly in Cal., Tex.,
> and Fla (as of 1/29/22)… Sales by category in fiscal ’21:
> beauty/household, 26%; hardlines, 18%; apparel/accessories,
> 17%; food, 20%; and home furnish., 19%.
This mega-sized company (annual revenue > $50B) has grown sales and earnings 3.4% and 13.1% per year over the last 10 years, respectively. Lines are mostly up except for dips in sales (’16) and EPS (’13 and ’16). PTPM over the last decade has ranged from 4.3% (’14) to 8.4% (’21) with a last-5-year average of 5.9%. This is higher than peer and industry averages.
ROE has trended up over the last 10 years from 18% (’12) to 32.5% in ’20 (’21 was an upside outlier at 48.1%) with a last 5-year average (excluding ’21) of 28.1%. This is higher than peer and industry averages. Debt-to-Capital has increased from 49.4% (’12) to 56.2% (’21) with a last-5-year average of 53.1%. This is also higher than peer and industry averages. Current Ratio is a suboptimal 0.86, but Interest Coverage is 10.8. M* assigns an Exemplary capital allocation rating while Value Line gives a B++ grade for financial strength.
I assume long-term annualized sales growth of 2% based on the following:
- CNN Business projects 2.5% YOY and 2.2% per year for ’22 and ’21-’23, respectively (based on 31 analysts).
- YF projects YOY 2.3% and 2.2% for ’23 and ’24, respectively (29 analysts).
- Zacks projects YOY 2.3% and 2.8% for ’23 and ’24, respectively (12).
- Value Line projects 3.8% annualized growth from ’21-’26 (11% from ’20-’26).
- CFRA projects growth of 2.8% YOY and 2.3% per year for ’23 and ’22-’24, respectively.
- M* provides a 2-year ACE of 2.1% and a 10-year estimate of 3% in its analyst note.
>
My estimate is just below all of the above.
I assume long-term annualized EPS growth of 2% based on the following:
- CNN Business projects a 59.3% YOY contraction and 17% contraction per year for ’22 and ’21-’23, respectively (based on 31 analysts), along with 5-year annualized contraction of 4.2%.
- MarketWatch projects annualized contraction of 15.9% and 5.5% for ’22-’24 and ’22-’25, respectively (36 analysts).
- Nasdaq.com projects annualized growth of 42.6% and 36.5% for ’23-’25 and ’23-’26, respectively [16, 10, and 2 analysts for ’23, ’25, and ’26].
- Seeking Alpha projects 5-year annualized growth of 10.5%.
- YF projects 59.1% YOY contraction and 70% YOY growth for ’23 and ’24, respectively (33), along with 5-year annualized contraction of 4.9%.
- Zacks projects 59.2% YOY contraction and 71.4% YOY growth for ’23 and ’24, respectively (16), along with 5-year annualized growth of 9.9%.
- Value Line projects annualized growth of 5.8% from ’21-’26.
- CFRA projects 56.8% YOY contraction and 15.9% contraction per year for ’23 and ’22-’24, respectively, and 1% growth per year from ’21-‘24%.
- M* projects long-term annualized growth of 4.8%.
>
I am projecting below the average [of six] long-term estimate[s] (3.6%).
I will override to project earnings from the last annual data point rather than Q3 ’22. Analyst consensus expects a big rebound in earnings for ’23, which is suggestive of a one-year anomaly due to the macroeconomic factors rather than maturation in business cycle. The latter has already occurred for this company.
The ideal situation would be to project from the same point analysts are using for their calculations, but because this is not explicitly disclosed, I have to do my best to work around it. Here, projection from the last quarterly data point or EPS trendline makes no sense because Forecast High Stock Price would be at or below the current stock price.
My Forecast High P/E is 17. Over the last 10 years, high P/E has ranged from 14.6 (’12) to 23.9 (’13) with a last-5-year average of 18.8.
My Forecast Low P/E is 10. Over the last 10 years low P/E has ranged from 9.1 (’17) to 18.2 (’13). The last-5-year average is 10.6. As suggested above, I think Target is a mature company so I don’t expect the kind of P/E compression that might be seen with a younger, more explosive growth company.
I’ve realized that I need to be very careful with the website and future EPS projection. Overriding the base on the estimated EPS growth rate screen leaves TTM EPS for the Low Stock Price Forecast. The latter may require changing as well.
My Low Stock Price Forecast is $137. The default value would be $141. This corresponds to ’21 earnings of $14.10/share and assumes 0% growth for the next five years. With the 52-week low price at $137.2, I’m overriding with $13.70/share to [roughly] match. $137 is 19.4% below the previous close.
Over the last 10 years, Payout Ratio has ranged from 22.4% (’21) to 51.5% (’13). The last-5-year average is 37.2%. I am assuming 31%.
All this computes to an U/D ratio of 2.9, which makes TGT a HOLD. The Total Annualized Return is 11.1%, and PAR (using Forecast Average, not High, P/E) is 6.6%, which is less than desired. Can I convince myself that the inherent margin of safety (MOS) in this study allows for a good chance of realizing Forecast High P/E?
To answer this, I compare my inputs with the larger sample size of Member Sentiment (MS). Out of 192 studies over the past 90 days (my own and four others with projected low prices above last closing price excluded), projected sales, projected EPS, Forecast High P/E, Forecast Low P/E, and Payout Ratio average 4.7%, 7.8%, 18.4, 11.3, and 38.4%, respectively. My inputs—especially the growth rates—are all lower. Value Line projects an average annual P/E of 15, which is barely higher than MS (14.9) and higher than mine (13.5). All this is indicative of a healthy MOS.
MS provides a[n] [average] Low Stock Price Forecast of $97.58, which is 28.8% lower than mine. It’s also closer to the 2020 [COVID crash] low of $90.20. In my opinion, a stock price five years from now > 20% below today’s price is almost unfathomable for [even] a[n] [anemic] growth company. This legitimizes my Low Stock Price Forecast. Forecasting close to the ’20 lows almost seems preposterous. I’d be curious to know if these MS studies were accompanied by a manual EPS override.
A significantly lower Low Stock Price Forecast would move TGT further into the Hold zone, but because this seems unreasonable I choose to ignore it as an offset to the MOS. The only remaining question in my mind is why CNN Business (FactSet) and YF (Refinitiv) project negative 5-year earnings growth when the other four do not.
That concern aside, I feel comfortable with TGT as a BUY under $169/share.
>
*—Publishing in arrears as I’ve been doing one daily stock study while posting only two blogs per week.